Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

IT-141

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Intezyne

Drug class:

Topoisomerase II inhibitor, Topoisomerase I inhibitor, Apoptosis stimulant

Related drugs:

‹

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

epirubicin (29)

daunorubicin (20)

cytarabine/daunorubicin liposomal formulation (19)

idarubicin hydrochloride (16)

mitoxantrone (16)

dactinomycin (8)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

lurbinectedin (11)

arsenic trioxide (6)

omacetaxine mepesuccinate (4)

quaratusugene ozeplasmid (3)

teserpaturev (1)

ABI-1968 topical cream (0)

autologous γδ T lymphocytes (0)

84AA-API 14AA (0)

alpha-tocopheroloxyacetic acid (0)

darinaparsin (0)

elemene injection (0)

BS-HH-002.SA (0)

›

ABCG2 overexpression

TP-3654 + IT-141

Sensitive: D – Preclinical

TP-3654 + IT-141

TP-3654 + IT-141

Sensitive: D – Preclinical

TP-3654 + IT-141